Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
09:15am, Wednesday, 03'rd Sep 2025
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:05am, Friday, 15'th Aug 2025
Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUST
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
09:15am, Thursday, 14'th Aug 2025
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical compa
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
08:45am, Tuesday, 22'nd Jul 2025
– Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing i
CNS Pharmaceuticals Announces Reverse Stock Split
08:00am, Friday, 18'th Jul 2025
HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
09:32am, Wednesday, 09'th Jul 2025
HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
08:05am, Thursday, 05'th Jun 2025
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire /
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
08:05am, Friday, 16'th May 2025
Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multi
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
09:35am, Tuesday, 13'th May 2025
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
07:00am, Tuesday, 13'th May 2025
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Manag
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
08:05am, Tuesday, 01'st Apr 2025
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical eff
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
12:05pm, Tuesday, 25'th Mar 2025
CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
08:00am, Tuesday, 25'th Mar 2025
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety pr
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
09:05am, Wednesday, 26'th Feb 2025
Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopha
